Pre-Clinical Investigation Laboratory - Lung cancer
The Pre-clinical investigation laboratory (LIP) has 25 years of experience in developing patient-derived xenografts of a wide range of cancers including breast, colon, lung, ovary, uveal melanoma, retinoblastoma, Head and Neck cancers.
The Pre-clinical investigation laboratory is developing the next generation of PDX models, from drug-resistant tumors, metastatic cancer to humanized models. LIP services include:
• Preclinical pharmacology & pharmacodynamics of anti-cancer drugs
• Identification of predictive biomarkers of response and resistance to anti-cancer agents
• Collaboration with many national and European academics & pharmaceutical companies
We have established a collection of heterotopic PDXs from primary and metastatic non-small cell lung cancers, coupled with molecular annotation including cancer panel targeted sequencing as well as gene expression.
The Pre-clinical investigation laboratory is a member of the EurOPDX Consortium. EurOPDX is supported by the European Union's Horizon 2020 research and innovation program under the grant agreement No. 731105 EDIReX